Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 71
Filter
1.
Drug Dev Res ; 84(8): 1699-1708, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37688413

ABSTRACT

Dengue fever is an acute febrile disease caused by dengue virus (DENV) infection. Over the past 60 years, DENV has spread throughout tropical regions and currently affects more than 50% of the world's population; however, there are as of yet no effective anti-DENV drugs for clinical treatment. A number of research teams have investigated derivatives of glycolipids as possible agents for the inhibition of DENV. Our objective in this research was to study the antiviral effects of trehalose 6-caprate (TMC), trehalose 6-monolaurate (TML), and trehalose 6-monooleate (TMO), based on reports that the corresponding glycosyl, trehalose, reduces the transmission of Zika virus (ZIKV). We also sought to elucidate the molecular mechanisms underlying inhibition using the RNA isolation and reverse transcription-quantitative polymerase chain reaction, western blot analysis, median tissue culture infectious dose (TCID50 ) assay, and immunofluorescence assay and immunochemistry staining, in vitro. This is the first study to demonstrate the TML-induced inhibition of DENV serotype 2 (DENV-2) in a dose-dependent manner. The inhibitory effects of TML in the pretreated, cotreated, and full-treated groups were confirmed using time of addition assays. We determined that TML restricted viral binding, entry, replication, and release. We also confirmed the efficacy of TML against three clinical isolates of DENV serotypes 1, 3, and 4 (DENV-1, DENV-3, and DENV-4). The findings obtained in this study identify TML as a promising candidate for the development of drugs to treat DENV infection.


Subject(s)
Dengue Virus , Dengue , Zika Virus Infection , Zika Virus , Humans , Dengue Virus/genetics , Dengue/drug therapy , Dengue/epidemiology , Zika Virus/genetics , Zika Virus Infection/epidemiology , Trehalose/pharmacology , Trehalose/therapeutic use
2.
Int J Med Sci ; 19(7): 1198-1204, 2022.
Article in English | MEDLINE | ID: mdl-35919812

ABSTRACT

Oral squamous cell carcinoma (OSCC) is particularly prevalent in Taiwan. The goal of this study was to determine the clinicopathological role of insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2) proteins as an indicator of clinical outcomes in OSCC patients. In this study, immunohistochemical (IHC) analysis was used to examine IGF2BP2 protein expression in 244 OSCC patients. We investigated the relationships among IGF2BP2 expression, clinicopathological variables, and patient survival. Our results showed that IGF2BP2 cytoplasmic protein expression was significantly correlated with lymph node metastasis, cancer stage, and patient survival. Kaplan-Meier survival curves revealed that elevated cytoplasmic IGF2BP2 expression levels in OSCC patients were associated with poor overall survival. Moreover, multivariate cox proportional hazard models revealed that cytoplasmic IGF2BP2 expression, T status, and lymph node metastasis were independent prognostic factors for survival. In conclusion, IGF2BP2 protein was found to be a helpful predictive marker for OSCC patients, as well as a possible therapeutic target for OSCC treatment.


Subject(s)
Head and Neck Neoplasms , RNA-Binding Proteins/metabolism , Squamous Cell Carcinoma of Head and Neck , Biomarkers, Tumor/metabolism , Head and Neck Neoplasms/metabolism , Head and Neck Neoplasms/mortality , Head and Neck Neoplasms/physiopathology , Humans , Kaplan-Meier Estimate , Lymphatic Metastasis , Prognosis , Squamous Cell Carcinoma of Head and Neck/metabolism , Squamous Cell Carcinoma of Head and Neck/mortality , Squamous Cell Carcinoma of Head and Neck/physiopathology
3.
FASEB J ; 34(8): 11215-11226, 2020 08.
Article in English | MEDLINE | ID: mdl-32648603

ABSTRACT

Gouty arthritis is the one of the most painful arthritis and is caused by an inflammatory reaction. This study investigated whether astaxanthin (AXT), which has documented anti-inflammatory and antioxidant properties, exhibits protective effects against monosodium urate (MSU) crystal-induced inflammation. Cell viability of J774A.1 murine macrophages was assessed by AXT dose-dependent incubation by MTT assays, and expression levels of iNOS and COX-2 proteins as well as secretion of IL-1ß were also analyzed under MSU crystals stimulation with or without AXT treatment. The production of inflammatory mediators was found to significantly decrease with AXT treatment, and the formation of the inflammasome complex was also attenuated when cells were co-stimulated with MSU crystals and AXT. Furthermore, we found that expression of the MAPK pathway was downregulated in J774A.1 cells. AXT also inhibited the induction of COX-2 and IL-6 in human chondrocytes and synovial fibroblasts by western blots. Finally, an MSU crystal intra-articular injection rat model for gouty arthritis was utilized in which treatment groups received 5-daily intraperitoneal injections of AXT prior to MSU crystal stimulation, or once intra-articular injections of AXT following MSU crystal stimulation for 6 hours. Results of synovitis score analysis revealed that inflammation was significantly attenuated in the group which received intraperitoneal AXT injection prior to MSU crystal stimulation compared to the group which received MSU only. These results indicate that AXT attenuates the effects of MSU crystal-induced inflammation by suppressing the production of pro-inflammatory cytokines and inflammatory mediators. Our findings that the anti-inflammatory activities of AXT may be beneficial in the treatment of MSU crystal-induced arthritis.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Inflammation/drug therapy , Joints/drug effects , Uric Acid/pharmacology , Animals , Arthritis, Gouty/chemically induced , Arthritis, Gouty/drug therapy , Arthritis, Gouty/metabolism , Cells, Cultured , Chondrocytes/drug effects , Chondrocytes/metabolism , Cyclooxygenase 2/metabolism , Cytokines/metabolism , Fibroblasts/drug effects , Fibroblasts/metabolism , Humans , Inflammation/metabolism , Interleukin-1beta/metabolism , Interleukin-6/metabolism , Joints/metabolism , Macrophages/drug effects , Macrophages/metabolism , Male , Mice , Rats , Rats, Sprague-Dawley , Synovitis/drug therapy , Synovitis/metabolism , Xanthophylls/pharmacology
4.
PLoS Biol ; 16(1): e2003714, 2018 01.
Article in English | MEDLINE | ID: mdl-29337987

ABSTRACT

Altered metabolism is one of the hallmarks of cancers. Deregulation of ribose-5-phosphate isomerase A (RPIA) in the pentose phosphate pathway (PPP) is known to promote tumorigenesis in liver, lung, and breast tissues. Yet, the molecular mechanism of RPIA-mediated colorectal cancer (CRC) is unknown. Our study demonstrates a noncanonical function of RPIA in CRC. Data from the mRNAs of 80 patients' CRC tissues and paired nontumor tissues and protein levels, as well as a CRC tissue array, indicate RPIA is significantly elevated in CRC. RPIA modulates cell proliferation and oncogenicity via activation of ß-catenin in colon cancer cell lines. Unlike its role in PPP in which RPIA functions within the cytosol, RPIA enters the nucleus to form a complex with the adenomatous polyposis coli (APC) and ß-catenin. This association protects ß-catenin by preventing its phosphorylation, ubiquitination, and subsequent degradation. The C-terminus of RPIA (amino acids 290 to 311), a region distinct from its enzymatic domain, is necessary for RPIA-mediated tumorigenesis. Consistent with results in vitro, RPIA increases the expression of ß-catenin and its target genes, and induces tumorigenesis in gut-specific promotor-carrying RPIA transgenic zebrafish. Together, we demonstrate a novel function of RPIA in CRC formation in which RPIA enters the nucleus and stabilizes ß-catenin activity and suggests that RPIA might be a biomarker for targeted therapy and prognosis.


Subject(s)
Aldose-Ketose Isomerases/metabolism , Aldose-Ketose Isomerases/physiology , beta Catenin/physiology , Adenomatous Polyposis Coli/metabolism , Adult , Aged , Animals , Animals, Genetically Modified , Carcinogenesis , Cell Line, Tumor , Cell Nucleus , Cell Proliferation/physiology , Cell Transformation, Neoplastic , Colorectal Neoplasms/genetics , Colorectal Neoplasms/metabolism , Female , Humans , Male , Middle Aged , Phosphorylation , Promoter Regions, Genetic/genetics , Protein Domains , RNA, Messenger/genetics , Ubiquitination , Zebrafish , beta Catenin/genetics
5.
Medicina (Kaunas) ; 57(2)2021 Feb 12.
Article in English | MEDLINE | ID: mdl-33673355

ABSTRACT

Background and Objectives: Oral squamous cell carcinoma (OSCC) is a malignant disease with a particularly high incidence in Taiwan. Our objective in this study was to elucidate the involvement of sphingolipid transporter 2 (SPNS2) expression and SPNS2 protein expression in the clinicopathological indexes and the clinical outcomes of OSCC patients. Materials and Methods: Immunohistochemistry analysis was performed for SPNS2 protein expression in samples from 264 cases of OSCC. Correlations of SPNS2 expression with clinicopathological variables and patient survival were analyzed. Results: Our results revealed that the cytoplasmic protein expression of SPNS2 in OSCC tissue specimens was lower than in normal tissue specimens. Negative cytoplasmic protein expression of SPNS2 was significantly correlated with T status and stage. Kaplan-Meier survival curve analysis revealed that negative cytoplasmic SPNS2 expression was predictive of poorer overall survival of OSCC patients in stage III/IV. We also determined that low SPNS2 expression was an independent prognostic factor related to overall survival among OSCC patients in stage III/IV from univariate Cox proportional hazard models. Multivariate Cox proportional hazard models revealed that cytoplasmic SPNS2 expression, T status, lymph node metastasis, and histological grade were independent prognostic factors for survival. Conclusions: Overall, this study determined that SPNS2 protein may be a useful prognostic marker for OSCC patients and potential therapeutic target for OSCC treatment.


Subject(s)
Anion Transport Proteins , Mouth Neoplasms , Squamous Cell Carcinoma of Head and Neck , Biomarkers, Tumor , Humans , Prognosis , Taiwan
6.
Medicina (Kaunas) ; 57(9)2021 Aug 28.
Article in English | MEDLINE | ID: mdl-34577821

ABSTRACT

Background and Objectives: Gouty arthritis is an acute inflammatory response caused by the precipitation of monosodium urate (MSU) crystals in joints. The triggering of MSU leads to increased production of inflammatory cytokines, such as interleukin-1ß, which in turn lead to the formation of macromolecular complexes, referred to as inflammasomes. Thorough characterization of the NLRP3 inflammasome can be used as an indicator of an immune response against harmful stimuli. Cardamonin is a chalcone, mainly found in the seeds of Alpinia katsumadai, and exhibits anti-inflammatory activity by inhibiting the release of pro-inflammatory cytokines in vitro. However, the mechanism by which cardamonin treatment alleviates gouty arthritis has yet to be fully elucidated. Materials and Methods: In vitro or in vivo models were used to study whether cardamonimn inhibited NLRP3 inflammasome activation or suppressed gouty inflammation. Results: In the current study, we determined that most NLRP3 was released passively after MSU stimulation, and this release of NLRP3 promoted caspase-1 activation and IL-1ß secretion. Cardamonin was shown to decrease both the activity of caspase-1 and secretion of IL-1ß in J774A.1 macrophage cells subjected to MSU stimulation. Cardamonin was also shown to attenuate the production of COX-2 in MSU-stimulated J774A.1 macrophage cells. Finally, cardamonin reduced the thickness of the synovial lining and the infiltration of gouty arthritis in a rat model. Conclusions: Overall, cardamonin significantly attenuated IL-1ß secretion, caspase-1 activity, and COX-2 production stimulated by MSU. These findings provide new insights into the molecular mechanisms underlying the effects of cardamonin treatment for gouty arthritis.


Subject(s)
Arthritis, Gouty , Chalcones , Animals , Arthritis, Gouty/chemically induced , Arthritis, Gouty/drug therapy , Chalcones/pharmacology , Chalcones/therapeutic use , Inflammasomes , NLR Family, Pyrin Domain-Containing 3 Protein , Rats , Uric Acid
7.
Biochem Biophys Res Commun ; 522(4): 1052-1058, 2020 02 19.
Article in English | MEDLINE | ID: mdl-31818462

ABSTRACT

The Zika virus (ZIKV) is a mosquito-borne flavivirus that has reemerged as a serious public health problem around the world. Syndromes of infected people range from asymptomatic infections to severe neurological disorders, such as Guillain-Barré syndrome and microcephaly. Screening anti-ZIKV drugs derived from Chinese medicinal herbs is one method of identifying antiviral agents. In this paper, we report that (1) Cephalotaxine (CET), an alkaloid isolated from Cephalotaxus drupacea, was effective in inhibiting ZIKV activity in vitro (i.e., in Vero and A549 cell lines) and (2) the mechanisms which underlie these effects involve virucidal activity and a decrease in viral replication. Specifically, CET was found to decrease ZIKV RNA and viral protein expression, inhibit ZIKV replication, and inhibit ZIKV mRNA/protein production. We also determined that CET is effective in inhibiting dengue virus 1-4 (DENV1-4). Taken together, our findings indicate that CET could be an effective lead compound in the treatment of ZIKV and also suggest that further investigation and development of CET-derived drugs may lead to a new class of anti-Flavivirus medications.


Subject(s)
Homoharringtonine/pharmacology , Virus Replication/drug effects , Zika Virus Infection/virology , A549 Cells , Animals , Chlorocebus aethiops , Dengue Virus/drug effects , Humans , RNA Stability/drug effects , RNA, Viral/biosynthesis , Serotyping , Vero Cells
8.
Molecules ; 25(18)2020 Sep 07.
Article in English | MEDLINE | ID: mdl-32906689

ABSTRACT

Mosquito-borne Zika virus (ZIKV) is a Flavivirus that came under intense study from 2014 to 2016 for its well-known ability to cause congenital microcephaly in fetuses and neurological Guillain-Barré disease in adults. Substantial research on screening antiviral agents against ZIKV and preventing ZIKV infection are globally underway, but Food and Drug Administration (FDA)-approved treatments are not available yet. Compounds from Chinese medicinal herbs may offer an opportunity for potential therapies for anti-ZIKV infection. In this study, we evaluated the antiviral efficacy of harringtonine against ZIKV. Harringtonine possessed anti-ZIKV properties against the binding, entry, replication, and release stage through the virus life cycle. In addition, harringtonine have strong virucidal effects in ZIKV and exhibited prophylaxis antiviral ability prior ZIKV infection. The antiviral activity also observed in the treatment against Japanese encephalitis reporter virus (RP9-GFP strain). Overall, this study demonstrated that harringtonine would be a favorable potential candidate for the development of anti-ZIKV infection therapies.


Subject(s)
Antiviral Agents/pharmacology , Harringtonines/pharmacology , Zika Virus Infection/virology , Zika Virus/drug effects , Animals , Antiviral Agents/chemistry , Cells, Cultured , Chlorocebus aethiops , Harringtonines/chemistry , Humans , Models, Molecular , Molecular Conformation , Structure-Activity Relationship , Vero Cells , Viral Envelope Proteins/antagonists & inhibitors , Viral Envelope Proteins/chemistry , Virus Attachment/drug effects , Virus Internalization/drug effects , Virus Release , Virus Replication/drug effects , Zika Virus/genetics , Zika Virus Infection/drug therapy
9.
Medicina (Kaunas) ; 56(10)2020 Oct 05.
Article in English | MEDLINE | ID: mdl-33028028

ABSTRACT

The clinical spectrum of novel coronavirus infection appears to be wide, encompassing asymptomatic infection, mild upper respiratory tract illness, and severe viral pneumonia, with respiratory failure and even death. Autoantibodies, especially antiphospholipid antibodies, can occur in severe infections. Other autoantibodies are seldom reported. Here, a 60-year-old female patient without dry-mouth symptoms detected positive for anti-60 kDa SSA/Ro antibodies on day 43 after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. To investigate this unique clinical case of SARS-CoV-2 infection, immunological characteristics of this case were detected by using flow cytometry and were compared to the other three groups of patients-health subjects, 2019 novel coronavirus disease (COVID-19) recovery patients, and Sjögren's syndrome (SS) patients. Monitoring the autoantibody level and the development of subsequently related autoimmune diseases are warranted after SARS-CoV-2 infection.


Subject(s)
Antibodies, Antinuclear/immunology , Antibodies, Viral/immunology , Betacoronavirus/immunology , Coronavirus Infections/immunology , Immunophenotyping , Pneumonia, Viral/immunology , COVID-19 , Female , Flow Cytometry , Humans , Middle Aged , Pandemics , SARS-CoV-2 , Sjogren's Syndrome
10.
Carcinogenesis ; 40(3): 461-473, 2019 05 14.
Article in English | MEDLINE | ID: mdl-30418535

ABSTRACT

Dysregulation of the enzymes involved in the pentose phosphate pathway (PPP) is known to promote tumorigenesis. Our recent study demonstrated that ribose-5-phosphate isomerase (RPIA), a key regulator of the PPP, regulates hepatoma cell proliferation and colony formation. Our studies in zebrafish reveal that RPIA-mediated hepatocarcinogenesis requires extracellular signal-regulated kinase (ERK) and ß-catenin signaling. To further investigate RPIA-mediated hepatocarcinogenesis, two independent lines of transgenic zebrafish expressing human RPIA in the liver were generated. These studies reveal that RPIA overexpression triggers lipogenic factor/enzyme expression, steatosis, fibrosis and proliferation of the liver. In addition, the severity of fibrosis and the extent of proliferation are positively correlated with RPIA expression levels. Furthermore, RPIA-mediated induction of hepatocellular carcinoma (HCC) requires the ERK and ß-catenin signaling pathway but is not dependent upon transaldolase levels. Our study presents a mechanism for RPIA-mediated hepatocarcinogenesis and suggests that RPIA represents a valuable therapeutic target for the treatment of HCC.


Subject(s)
Aldose-Ketose Isomerases/metabolism , Extracellular Signal-Regulated MAP Kinases/metabolism , Liver Neoplasms, Experimental/pathology , beta Catenin/metabolism , Animals , Animals, Genetically Modified , Cell Line, Tumor , Disease Progression , Liver Neoplasms, Experimental/enzymology , Liver Neoplasms, Experimental/metabolism , Zebrafish/genetics
11.
Biochem Biophys Res Commun ; 518(4): 732-738, 2019 10 22.
Article in English | MEDLINE | ID: mdl-31472967

ABSTRACT

Zika virus (ZIKV) is an emerging vector-borne virus that is associated with severe congenital cerebral anomalies in fetuses and paralytic Guillain-Barré syndrome in adults. In the current global health crisis, there are no vaccines or therapeutics available for the treatment of ZIKV infection. In the present study, we evaluated the efficacy of the protoberberine alkaloid, palmatine, in inhibiting ZIKV and Japanese encephalitis virus (JEV). Palmatine was shown to bind to restricted viruses, inhibit ZIKV infection, and resist ZIKV-induced cytopathic effects. Palmatine was also shown to inhibit JEV infection in multiple cell lines. Overall, the effects of palmatine in disrupting ZIKV binding, entry, and stability indicate that this small molecule would be a good starting point for the development of treatments aimed at inhibiting ZIKV infection.


Subject(s)
Berberine Alkaloids/pharmacology , Cytopathogenic Effect, Viral/drug effects , Virus Attachment/drug effects , Virus Internalization/drug effects , Virus Replication/drug effects , Zika Virus/drug effects , A549 Cells , Animals , Cell Line , Chlorocebus aethiops , Dose-Response Relationship, Drug , Humans , RNA, Viral/genetics , RNA, Viral/metabolism , Vero Cells , Virus Replication/genetics , Zika Virus/genetics , Zika Virus/physiology , Zika Virus Infection/prevention & control , Zika Virus Infection/virology
12.
Biochem Biophys Res Commun ; 517(1): 155-163, 2019 09 10.
Article in English | MEDLINE | ID: mdl-31353084

ABSTRACT

Osteoarthritis (OA) is a common degenerative joint disease characterized by progressive deterioration of articular cartilage. There have been reports that small molecule inhibitors have anti-osteoarthritis effects; however, the effects of 3-(4-chloro-2-fluorophenyl)-6-(2,4-difluorophenyl)-2H-benzo[e] [1,3]oxazine-2,4(3H)-dione (Cm-02) and 6-(2,4-difluorophenyl)-3-(3,4-difluorophenyl)-2H-benzo[e] [1,3]oxazine-2,4(3H)-dione (Ck-02), small molecule inhibitors which share many structural similarities with quercetin (a potent anti-inflammatory flavonoid), remain unclear. In this study, TNF-α-stimulated porcine and human chondrocyte models were used to investigate the inhibitory effects of Cm-02 and Ck-02 on the molecular mechanisms underlying the anti-OA effects. TNF-α was used to stimulate porcine and human chondrocytes to mimic immunomodulatory potency in-vitro. Anti-osteoarthritic effects were characterized in terms of protein and mRNA levels associated with the pathogenesis of OA. We also examined (1) the inducible nitric oxide synthase (iNOS)-nitric oxide (NO) system in cultured chondrocytes, (2) matrix metalloproteinases (MMPs) in cultured chondrocytes, and (3) aggrecan degradation in cartilage explants. Finally, we tested the activation of nuclear factor-kappaB (NF-κB), interferon regulatory factor-1 (IRF-1), and activate the protein-1 (AP-1), and we tested the signal transduction and activation of transcription-3 (STAT-3). Our results indicate that, in chondrocytes, Cm-02 and Ck-02 inhibit TNF-α induced NO production, iNOS, MMP, the expression of disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS), and the enzyme activity of MMP-13. Furthermore, both Cm-02 and Ck-02 were found to stimulate TNF-α, which has been shown to suppress the activation of several transcription factors, including NF-κB, STAT-3, and IRF-1 in porcine and human chondrocytes. Cm-02 and Ck-02 were also found to help prevent the release of proteoglycans from cartilage explants. Our findings demonstrate that both Cm-02 and Ck-02 have potent anti-inflammatory activities and the ability to protect cartilage in an OA cell model. These findings indicate that Cm-02 and Ck-02 have the potential to be further developed for the therapeutic treatment of OA.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Benzoxazines/pharmacology , Chondrocytes/drug effects , Osteoarthritis/drug therapy , Animals , Anti-Inflammatory Agents/chemistry , Benzoxazines/chemistry , Cells, Cultured , Chondrocytes/immunology , Halogenation , Humans , NF-kappa B/immunology , Nitric Oxide/immunology , Nitric Oxide Synthase Type II/immunology , Osteoarthritis/immunology , Swine , Tumor Necrosis Factor-alpha/immunology
13.
Gen Comp Endocrinol ; 277: 112-121, 2019 06 01.
Article in English | MEDLINE | ID: mdl-30926469

ABSTRACT

Hepatocellular carcinoma (HCC) shows clear sex disparity with men being more prone to developing HCC and having higher mortality than women. Previous studies have indicated that sex hormones play important roles in HCC initiation and development, but the effects of sex hormones on HCC in clinical trials remain inconsistent. Using zebrafish liver tumor model co-induced by oncogenes Myc and xmrk, we observed similar sex disparity between male and female zebrafish in liver tumor progression and regression; i.e. male Myc/xmrk transgenic zebrafish developed HCC significantly faster and regressed HCC significantly slower than female Myc/xmrk transgenic zebrtafish. To investigate the effects of sex hormones on liver tumor progression and regression, Myc/xmrk fish were treated with either androgen or estrogen, we observed that androgen promoted HCC progression and retarded HCC regression in females, while estrogen attenuated HCC progression and accelerated HCC regression in males. Furthermore, androgen promoted cell proliferation while estrogen inhibited it. Overall, the present study suggested that sex hormones affected liver tumor progression and regression in the Myc/xmrk transgenic zebrafish.


Subject(s)
Disease Progression , Gonadal Steroid Hormones/pharmacology , Liver Neoplasms/pathology , Oncogenes , Zebrafish Proteins/metabolism , Zebrafish/genetics , Animals , Animals, Genetically Modified , Carcinoma, Hepatocellular/pathology , Cell Proliferation/drug effects , Female , Male , Sex Characteristics , Zebrafish Proteins/genetics
14.
Biochem Biophys Res Commun ; 503(3): 1442-1449, 2018 09 10.
Article in English | MEDLINE | ID: mdl-30029884

ABSTRACT

In this study, we investigated the expression of jumonji domain-containing 4 (JMJD4) in colon adenocarcinoma (CA) look for evidences for future studies on clinical diagnostic and prognostic value. The immunohistochemical (IHC) reactivity of JMJD4 was assessed in human tissue microarrays using monoclonal antibodies. An initial investigation revealed that the expression of JMJD4 protein was significantly higher in tumor tissue of the colon and liver than in normal tissue. Upon further investigation, we observed significant positivity of JMJD4 between 59 paired samples from CA tissue and adjacent normal tissue. JMJD4 protein expression in CA differed significantly according to the histological grade and M-class (distant metastasis). We also determined that the mRNA or protein expression of JMJD4 was significantly associated with poor survival in patients with CA. Finally, univariate and multivariate analysis revealed that JMJD4 expression could be a prognostic indicator for patients with CA and may provide a new target for the development of novel therapies for the treatment of CA.


Subject(s)
Adenocarcinoma/genetics , Colonic Neoplasms/genetics , Mixed Function Oxygenases/genetics , Adenocarcinoma/diagnosis , Colonic Neoplasms/diagnosis , Female , Humans , Immunohistochemistry , Jumonji Domain-Containing Histone Demethylases , Male , Middle Aged , Mixed Function Oxygenases/analysis , RNA, Messenger/genetics , Survival Rate
15.
Int J Mol Sci ; 19(5)2018 May 14.
Article in English | MEDLINE | ID: mdl-29757957

ABSTRACT

In this study, we synthesized hundreds of analogues based on the structure of small-molecule inhibitors (SMIs) that were previously identified in our laboratory with the aim of identifying potent yet safe compounds for arthritis therapeutics. One of the analogues was shown to share structural similarity with quercetin, a potent anti-inflammatory flavonoid present in many different fruits and vegetables. We investigated the immunomodulatory effects of this compound, namely 6-(2,4-difluorophenyl)-3-(3-(trifluoromethyl)phenyl)-2H-benzo[e][1,3]oxazine-2,4(3H)-dione (Cf-02), in a side-by-side comparison with quercetin. Chondrocytes were isolated from pig joints or the joints of patients with osteoarthritis that had undergone total knee replacement surgery. Several measures were used to assess the immunomodulatory potency of these compounds in tumor necrosis factor (TNF-α)-stimulated chondrocytes. Characterization included the protein and mRNA levels of molecules associated with arthritis pathogenesis as well as the inducible nitric oxide synthase (iNOS)⁻nitric oxide (NO) system and matrix metalloproteinases (MMPs) in cultured chondrocytes and proteoglycan, and aggrecan degradation in cartilage explants. We also examined the activation of several important transcription factors, including nuclear factor-kappaB (NF-κB), interferon regulatory factor-1 (IRF-1), signal transducer and activator of transcription-3 (STAT-3), and activator protein-1 (AP-1). Our overall results indicate that the immunomodulatory potency of Cf-02 is fifty-fold more efficient than that of quercetin without any indication of cytotoxicity. When tested in vivo using the induced edema method, Cf-02 was shown to suppress inflammation and cartilage damage. The proposed method shows considerable promise for the identification of candidate disease-modifying immunomodulatory drugs and leads compounds for arthritis therapeutics.


Subject(s)
Protective Agents/chemistry , Protective Agents/pharmacology , Quercetin/chemistry , Quercetin/pharmacology , Animals , Arthritis/drug therapy , Arthritis/etiology , Arthritis/metabolism , Arthritis/pathology , Chondrocytes/drug effects , Chondrocytes/metabolism , Collagen/metabolism , Immunomodulation/drug effects , Matrix Metalloproteinase 13/metabolism , Nitric Oxide/metabolism , Nitric Oxide Synthase Type II/metabolism , Proteoglycans/metabolism , Structure-Activity Relationship , Swine , Transcription Factors/metabolism , Tumor Necrosis Factor-alpha/metabolism
16.
Biochem Biophys Res Commun ; 494(1-2): 173-180, 2017 12 09.
Article in English | MEDLINE | ID: mdl-29037809

ABSTRACT

To investigate the relationship between YY1AP1 and various clinicopathological features of colon adenocarcinoma (COAD), we conducted immunohistochemical (IHC) analyses of human tissue microarrays. We found that YY1AP1 protein expression was significantly higher in tumor tissue of the colon and liver, and was significantly lower in tumor tissue of the kidney. An analysis that employed the SurvExpress database indicated that increased expression of YY1AP1 mRNA was significantly associated with the overall survival of COAD patients. To clarify the validity of YY1AP1 or PCNA as determined by the IHC analysis was performed on 59 paired samples from COAD and adjacent normal tissue. Statistically significant differences of immunoreactivity for YY1AP1 or PCNA protein expression was observed between COAD tissue and adjacent normal tissue. High protein expression levels of YY1AP1 and PCNA were also found to be significantly correlated with M-class and distant metastasis. We also determined that YY1AP1 was correlated with PCNA expression in COAD samples, and Kaplan-Meier survival curves indicated that YY1AP1 protein expression was significantly associated with poor survival. Finally, a univariate analysis demonstrated that YY1AP1 protein expression was related to YY1AP1 score, and multivariate analysis revealed that the YY1AP1 protein expression level was an independent risk factor of overall COAD survival. Taken together, our findings indicate that YY1AP1 expression plays an important role in the tumorigenesis and progression of COAD and could serve as a clinical prognostic indicator for COAD.


Subject(s)
Adenocarcinoma/metabolism , Biomarkers, Tumor/metabolism , Colonic Neoplasms/metabolism , Nuclear Proteins/metabolism , Proliferating Cell Nuclear Antigen/metabolism , Transcription Factors/metabolism , Adenocarcinoma/genetics , Adenocarcinoma/pathology , Biomarkers, Tumor/genetics , Cell Cycle Proteins , Colonic Neoplasms/genetics , Colonic Neoplasms/pathology , Disease Progression , Female , Gene Expression , Humans , Immunohistochemistry , Male , Middle Aged , Nuclear Proteins/genetics , Prognosis , Proliferating Cell Nuclear Antigen/genetics , Proportional Hazards Models , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Neoplasm/genetics , RNA, Neoplasm/metabolism , Transcription Factors/genetics
17.
Biochem Biophys Res Commun ; 491(3): 595-602, 2017 09 23.
Article in English | MEDLINE | ID: mdl-28760340

ABSTRACT

Chikungunya is a severe disease that results from infection with the chikungunya virus (CHIKV), an arbovirus. Thus, we (1) explored a new approach to combining previously researched drugs that have shown the potential to inhibit CHIKV infection; and (2) demonstrated the antiviral effects of (-)-Epigallocatechin-3-gallate (EGCG) and the underlying mechanisms. Specifically, we used U2OS cells infected with CHIVK to assess the synergistic antiviral activities of EGCG and suramin. EGCG presented the ability to inhibit the viral RNA, progeny yield, and cytopathic effect (CPE) of CHIKV and also demonstrated the ability to protect against virus entry, replication, and release. Moreover, the results confirmed that EGCG and suramin can have synergistic effects against CHIKV strain S27 infection and two other clinical isolates of CHIKV. Our findings suggest that treatment with a combination of EGCG and suramin could provide a basis for the development of novel stretages against CHIKV infection.


Subject(s)
Catechin/analogs & derivatives , Chikungunya Fever/drug therapy , Chikungunya Fever/virology , Chikungunya virus/drug effects , Chikungunya virus/physiology , Suramin/administration & dosage , Antiviral Agents/administration & dosage , Catechin/administration & dosage , Dose-Response Relationship, Drug , Drug Combinations , Drug Synergism , Humans , Treatment Outcome
18.
Int J Cancer ; 137(1): 104-15, 2015 Jul 01.
Article in English | MEDLINE | ID: mdl-25429733

ABSTRACT

The deregulated nonoxidative pentose phosphate pathway (PPP) is known to promote oncogenesis, but the molecular mechanism remains unknown. Here, we report that human ribose-5-phosphate isomerase A (RPIA) plays a role in human hepatocellular carcinoma (HCC). A significant increase in RPIA expression was detected both in tumor biopsies of HCC patients and in a liver cancer tissue array. Importantly, the clinicopathological analysis indicated that RPIA mRNA levels were highly correlated with clinical stage, grade, tumor size, types, invasion and alpha-fetoprotein levels in the HCC patients. In addition, we demonstrated that the ability of RPIA to regulate cell proliferation and colony formation in different liver cancer cell lines required ERK signaling as well as the negative modulation of PP2A activity and that the effects of RPIA could be modulated by the addition of either a PP2A inhibitor or activator. Furthermore, the xenograft studies in nude mice revealed that the modulation of RPIA in liver cancer cells regulated tumor growth and that NIH3T3 cells overexpressing RPIA exhibited increased proliferation, enhanced colony formation, elevated levels of p-ERK1/2 and accelerated tumor growth. This study provides new insight into the molecular mechanisms by which RPIA overexpression can induce oncogenesis in HCC. Furthermore, it suggests that RPIA can be a good prognosis biomarker and a potential target for HCC therapy.


Subject(s)
Aldose-Ketose Isomerases/metabolism , Carcinoma, Hepatocellular/pathology , Liver Neoplasms/pathology , MAP Kinase Signaling System , Aldose-Ketose Isomerases/genetics , Animals , Carcinoma, Hepatocellular/enzymology , Carcinoma, Hepatocellular/genetics , Cell Line, Tumor , Cell Proliferation , Gene Expression Regulation, Neoplastic , Hep G2 Cells , Humans , Liver Neoplasms/enzymology , Liver Neoplasms/genetics , Mice , Mice, Nude , NIH 3T3 Cells , Neoplasm Transplantation , Protein Phosphatase 2/metabolism
19.
In Vivo ; 38(3): 1512-1518, 2024.
Article in English | MEDLINE | ID: mdl-38688598

ABSTRACT

BACKGROUND/AIM: Progressive fibrosing interstitial lung disease (PF-ILD) refers to a group of chronic lung conditions commonly associated with immunoglobulin G4-related disorders. It is characterized by progressive scarring (fibrosis) within the pulmonary interstitium, resulting in respiratory failure and early mortality. Some patients do not respond to standard therapeutic interventions. Numerous studies have confirmed the anti-inflammatory and antioxidant properties of molecular hydrogen in various disease models. CASE REPORT: In this report, we present a case study of an 85-year-old female diagnosed with suspected IgG4-related PF-ILD complicated by hospital-acquired pneumonia. On the fourth day of hydrogen-assisted therapy, a noticeable improvement in lung infiltrations was observed in chest X-rays as the patient gradually progressed towards weaning off mechanical ventilation. To assess treatment responses, we compared immune phenotypes before and after hydrogen treatment. A marked increase was observed in resting regulatory T cell levels after treatment, accompanied by a notable decrease in Fas+ helper T cell and cytotoxic T cell subtypes. CONCLUSION: This case study highlights the effectiveness of hydrogen-assisted therapy in managing PF-ILD complicated by pneumonia, warranting further research in the future.


Subject(s)
Hydrogen , Immunoglobulin G , Lung Diseases, Interstitial , T-Lymphocytes, Regulatory , Humans , Female , Aged, 80 and over , Lung Diseases, Interstitial/drug therapy , Lung Diseases, Interstitial/immunology , Lung Diseases, Interstitial/pathology , T-Lymphocytes, Regulatory/immunology , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism , fas Receptor/metabolism , Treatment Outcome
20.
In Vivo ; 38(3): 1316-1324, 2024.
Article in English | MEDLINE | ID: mdl-38688649

ABSTRACT

BACKGROUND/AIM: Our objectives in this study were to (i) evaluate the clinical significance of X-box-binding protein 1 (XBP1) expression in cases of hepatocellular carcinoma (HCC) and (ii) assess the potential of XBP1 to be used as a prognostic biomarker. PATIENTS AND METHODS: The expression of XBP1 protein in 267 HCC tissue specimens was measured using immunohistochemistry in order to characterize the associations among XBP1 expression, clinicopathological factors and survival outcomes. Survival analysis using follow-up data was used to assess the prognostic value of XBP1 in cases of HCC. Immunohistochemistry revealed a significant decrease in cytoplasmic XBP1 protein expression in HCC tumor tissue. RESULTS: Immunoreactivity results showed that low cytoplasmic XBP1 expression was significantly associated with vascular invasion, as well as poor 5-year overall survival and long-term disease-specific (DSS) and disease-free (DFS) survival rates. Kaplan-Meier survival curves further confirmed a significant association between low cytoplasmic XBP1 protein expression and poor DSS and DFS. Univariate and multivariate analyses revealed that XBP1 expression, tumor differentiation, vascular invasion, tumor stage, and the rate of recurrence were linked to DSS, while low cytoplasmic XBP1 expression remained an independent predictor of poor DSS. Our analysis also revealed that XBP1 expression, tumor differentiation, vascular invasion, and T classification were linked to DFS, while low cytoplasmic XBP1 expression remained an independent predictor of poor DFS. CONCLUSION: Low cytoplasmic XBP1 protein expression may play an important role in the pathogenesis of HCC, which suggests that XBP1 could potentially be targeted to benefit therapeutic strategies for HCC.


Subject(s)
Biomarkers, Tumor , Carcinoma, Hepatocellular , Cytoplasm , Liver Neoplasms , X-Box Binding Protein 1 , Humans , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/metabolism , Carcinoma, Hepatocellular/genetics , Carcinoma, Hepatocellular/mortality , Liver Neoplasms/pathology , Liver Neoplasms/metabolism , Liver Neoplasms/mortality , Liver Neoplasms/genetics , X-Box Binding Protein 1/metabolism , X-Box Binding Protein 1/genetics , Male , Female , Middle Aged , Cytoplasm/metabolism , Prognosis , Biomarkers, Tumor/metabolism , Aged , Adult , Immunohistochemistry , Kaplan-Meier Estimate , Neoplasm Staging
SELECTION OF CITATIONS
SEARCH DETAIL